Anthony Quinn cements Aeglea CEO spot; Human Longevity bumps David Karow up to the top
→ After proving himself in one year as interim CEO at Aeglea BioTherapeutics $AGLE, Anthony Quinn is officially taking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.